This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.
Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno
by Arpita Dutt
With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?
The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties
Top Research Reports for Intel, Honda & Biogen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Biogen (BIIB), Honda (HMC) and Intel (INTC).
Company News for November 08, 2016
by Zacks Equity Research
Companies in the News are: BRK.B,LC,BID,BIIB,IONS
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
Fundamentals Remain Strong in the Pharma Sector
by Arpita Dutt
We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.
Stock Market News for October 12, 2016
by Zacks Equity Research
Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday
6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings
by Zacks Equity Research
A number of healthcare companies are recording improvements in their financial numbers.
Stock Market News for September 21, 2016
by Zacks Equity Research
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
Top 3 Research Reports for August 15, 2016
by Sheraz Mian
Today's must-read reports are for AstraZeneca (AZN), Caterpillar (CAT) and Exelon (EXC).
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
by Sheraz Mian
Today's must-read reports are for Intel (INTC), Biogen (BIIB) and AT&T (T).
Pharma Industry Outlook: Fundamentals Remain Strong
by Arpita Dutt
It's been a rough start to the year for pharma and biotech with several factors weighing on the sector.
Stock Market News for July 07, 2016
by Zacks Equity Research
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
Stock Market News for June 16, 2016
by Zacks Equity Research
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
Stock Market News for May 10, 2016
by Zacks Equity Research
Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
4 Biotech Stocks Looking Good this Earnings Season
by Zacks Equity Research
the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.
4 Health Care Stocks to Watch Out for this Earnings Season
by Zacks Equity Research
Health care companies have been attracting a lot of attention lately.
by Zacks Equity Research
The biotech segment has been growing well surpassing all expectations.
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss
by Zacks Equity Research
Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.
Stocks with Upgraded Broker Ratings
by Kevin Matras
Kevin Matras explains why looking for stocks with upgraded broker ratings can upgrade your portfolio to a whole new level. Highlighted stocks include BIIB, LUV, NFG, TOWR and XRS.